ACRO Biomedical Pioneers a New Era in Medical Advancements

From Cutting-Edge Regenerative Medicine to Groundbreaking Bionic Research

2024 has been a landmark year for ACRO Biomedical (6748), showcasing its technological prowess across regenerative medicine and bionic innovations. With its core technology and international collaborations, ACRO is unlocking new opportunities for the medical industry.

A Breakthrough in Medical Market: Decellularized Dermal Micro-Particle Technology

Versatile Applications from Wound Healing to Hair Regeneration

ACRO Biomedical has successfully developed the Decellularized Dermal Micro-Particle Technology based on its Supercritical CO2 Technology Platform. This innovation has shown remarkable results in wound care and tissue regeneration, with breakthrough progress in hair regeneration.

Dr. Dar-Jen Hsieh, Chairman of ACRO Biomedical, explains:
"By removing all cells and allergens while preserving the natural collagen scaffold structure, this technology provides an optimal environment for hair follicle stem cells to proliferate and differentiate rapidly."

The technology is poised to be a game-changer in the aesthetic medicine market, with significant milestones achieved this year:

• April: Received TFDA Class III Medical Device approval for Hemostatic Collagen Matrix, Hemostatic ADM Scaffold and Hemostatic ADM Paste.

• October: Received U.S. FDA 510(k)approval for ABCcolla^® Collagen ADM Scaffold..

• November: Won the 21st National Innovation Award in the Corporate Innovation Category, further validating its industry leadership.

With these achievements, ACRO Biomedical has firmly established itself as a global leader in regenerative medicine.

---

Advancing Brain-Machine Interfaces with Bionic Applications

Collaborating with Prof. Kuan-Chang Chang: ADM-Based Neuromorphic Device Unveils a New Era of Smart Healthcare

ACRO Biomedical has expanded its Supercritical CO2 Technology into the development of an ADM-based neuromorphic device, in partnership with Prof. Kuan-Chang Chang’s team. This innovation creates a bionic platform capable of directly interfacing with the nervous system, integrating:

• Collagen-based biomembranes with high biocompatibility.

• Precision microchips for seamless interaction with neural networks.

The applications of this technology include:

• Neural repair and disease monitoring: Promotes nerve regeneration and aids in tracking neurodegenerative diseases.

• Brain-machine interfaces: Enables seamless integration between artificial devices and the nervous system, driving bionic innovations forward.

This research was featured as the cover article in the October issue of the prestigious journal ACS Nano, solidifying its impact on the global scientific community.

---

Regenerative Medicine Legislation Paves the Way for Market Expansion

In June 2024, Taiwan passed the Regenerative Medicine Act and the Regenerative Medical Products Regulation, creating a favorable environment for the industry. This legislation reduces regulatory barriers, accelerates clinical trials, and provides fast-track approvals for innovative treatments.

ACRO Biomedical is leveraging this policy shift to expand its global footprint, particularly in wound care, dentistry, orthopedics, ophthalmology, and aesthetic medicine.

A key initiative is its 150-patient clinical trial in India for corneal transplantation, with the data supporting regulatory approvals in India, the U.S. (FDA), and the EU (CE certification). The trial is set to conclude within two years, marking a major step toward transforming global eye care.

Solving the Global Kidney Transplant Shortage with Decellularized Organs

Revolutionizing Kidney Regeneration

With over 90,000 dialysis patients in Taiwan and a severe shortage of transplant donors, ACRO Biomedical is pioneering kidney regeneration using Supercritical Decellularization Technology.

Dr. Hsieh explains:
"Our technology preserves the kidney’s natural scaffold structure, and in animal studies at Kaohsiung Medical University, transplanted kidneys in rabbits successfully regained urine production within four weeks."

To further this research, ACRO Biomedical is collaborating with:

• National Chung Hsing University’s College of Veterinary Medicine (providing experimental facilities and post-op monitoring).

• Tung’s Taichung MetroHarbor Hospital (conducting transplant surgeries).

The next phase involves xenotransplantation—testing decellularized pig kidneys in dogs, sheep, and primates. If successful, ACRO plans to apply for human clinical trials, offering hope to hundreds of thousands of kidney failure patients worldwide.

---

Expanding Product Applications: 48 Medical Device Approvals Worldwide

With 92 global patents and 48 regulatory approvals across multiple medical sectors—wound care, orthopedics, dentistry, ophthalmology, and aesthetic medicine—ACRO Biomedical continues to push the boundaries of regenerative medicine.

Looking ahead, ACRO is committed to expanding its technological frontiers, with organ regeneration as its ultimate goal.

URL:ACRO Biomedical Pioneers a New Era in Medical Advancements